NEW YORK, August 24, 2026, 14:00 EDT — Sandisk stock slid 7% as investors weighed the potential AI-driven premium in light of fresh risks to its Apple supply relationship and memory sales in China.
| Broker | View | Target | Date |
|---|---|---|---|
| Bernstein SocGen | BUY | $3,000 | Aug 17 |
| Citi | BUY | $2,100 | Aug 14 |
| Mizuho | BUY | $1,900 | Aug 14 |
| RBC Capital | HOLD | $1,600 | Aug 14 |
| Wells Fargo | HOLD | $1,550 | Aug 14 |
Tesla’s 2.98 million-vehicle action equals 11.2× its 2026 China retail sales through July.
Most remedies use warning labels and remote software, limiting workshop time and hardware expense.
July local deliveries fell 32.9% YoY to 27,249. Exports reached a record 66,330.
Monday’s move also reflects wider auto-sector pressure from new tariff threats. The recall should not be treated as the sole price catalyst.
| Firm | Call | Target |
|---|---|---|
| GLJ | Sell | $200 |
| Barclays | Hold | $370 |
| Wells Fargo | Sell | $130 |
| Morgan Stanley | Hold | $400 |
| DBS | Hold | $330 |
47-analyst consensus: Buy. Target range: $125–$600.
The stock opened below its August 20 launch-day close of $80.14. The completed-session tape does not support a post-launch $6 billion gain.
Market value rose $17.49B from August 17 to August 19. After the show launched, capitalization fell $2.62B through Friday.
Consensus: Buy · 51 analysts
| Firm | Call | Target |
|---|---|---|
| J.P. Morgan | Buy | $85 |
| BMO | Buy | $135 |
| DBS | Buy | $94 |
| Baird | Buy | $90 |
Bull case: fresh content supports retention, pricing and an ad business targeting about $3B in 2026 revenue.
Bear case: slower growth and limited title-level evidence leave investors paying about 23 times forward earnings without a clear engagement inflection.
The useful signal is the gap: Nasdaq 100 futures fell almost three times as much as Dow futures. Nvidia earnings and Wednesday's inflation data now carry more weight than the blue-chip headline.
Macro data lands first. A hotter reading would raise the hurdle for tech valuations.
The company call begins at 17:00 EDT. Guidance is likely to matter more than the headline beat.
Markets want a policy framework. Less guidance could leave long yields in control.
| Analyst | Firm | Call | Target | Aug. 24 action |
|---|---|---|---|---|
| Harlan Sur | J.P. Morgan | Buy | $280 | Reiterated |
| John Vinh | KeyBanc | Buy | $330 | Maintained |
| C.J. Muse | Cantor Fitzgerald | Buy | $350 | Maintained |
| Kevin Cassidy | Rosenblatt Securities | Buy | $325 | Maintained |
| Vijay Rakesh | Mizuho Securities | Buy | Not listed | Reiterated |
| Program | Status | Next event |
|---|---|---|
| GPS / REGAL Phase 3 | 78 of 80 events as of May 11 | 80th event → final analysis |
| SLS009 frontline AML | 28 of 80 patients enrolled | Topline Q4 2026 |
| SLS009 pancreatic | Preclinical | Conference data |
| Consensus | BUY |
| Average target | $32.50 |
| Maxim | $30 |
| Alliance Global | $35 |
Workday trades above Wall Street's stand-alone value as Silver Lake talks remain unconfirmed. Thursday's earnings can either support the premium or expose it.
Deal enthusiasm is real, but incomplete. The stock remains 11.7% below its $227.49 report-day high.
The premium exceeds Workday's last reported cash pile. It needs either a bid or faster growth.
Current equity value equals about 20.7 times annualized Q1 free cash flow. This is a simple run-rate, not guidance.
The rating says Buy. The average target says 10.1% downside. Takeover repricing created the contradiction.
| Metric | Reference | Investor test |
|---|---|---|
| Q2 subscription revenue | $2.455bn company guide | 13% growth |
| Q2 total revenue | ≈$2.64bn consensus | Maintain double-digit pace |
| Q2 adjusted EPS | ≈$2.61–$2.66 consensus | Protect margin story |
| Q2 non-GAAP margin | 30.0% company guide | No execution slip |
| FY subscription revenue | $9.925bn–$9.950bn guide | 12%–13% growth holds |
Price data: S&P Global via StockAnalysis, August 24, 2026, 06:40 EDT. Analyst data: StockAnalysis and Jefferies via The Fly. Results and guidance: Workday. Deal report: Reuters. Dashboard assembled August 24, 2026, 07:54 EDT. Calculations may differ due to rounding.
| Q2 2026 measure | Value | Signal |
|---|---|---|
| Revenue | $7.8B | +92% YoY |
| Adjusted EBITDA | $3.5B | +191% YoY |
| Net loss | $541M | narrowed |
| Capital expenditure | $18.4B | 2.4× revenue |
| AI capex | $15.8B | 86% of capex |
NIO Inc. · overseas optionality versus Chinese operating leverage
The stock recovered Friday but remained 42.3% below its $8.02 52-week high. Monday's premarket reversal returned focus to execution risk.
NIO scopes include Firefly where reported. The scale difference makes Europe a strategic signal, not a near-term earnings driver.
| Measure | Q1'26 | Q4'25 | Q1'25 |
|---|---|---|---|
| Revenue | 25.53bn | 34.65bn | 12.03bn |
| Gross margin | 19.0% | 17.5% | 7.6% |
| Vehicle margin | 18.8% | 18.1% | 10.2% |
| Adj. operating P/(L) | 66.8m | 1.25bn | −5.95bn |
| Cash & liquid funds | 48.2bn | 45.9bn | — |
Q2 deliveries were 107,658, below NIO's 110,000–115,000 guidance. September 1 will reveal the margin cost.
| What to watch | Bull case | Bear case |
|---|---|---|
| Vehicle margin | Holds near 18.8% | Discounting breaks the trend |
| Cash conversion | Fourth positive operating-cash quarter | Working-capital reversal |
| August deliveries | Reaccelerate above July's 35,934 | Sequential decline persists |
| Europe plan | New platform timetable or distributors | Old stock lasts into late 2027 |
Marvell's Google agreement can unlock $120 billion of purchases. The market is now weighing that scale against earnings execution and a warrant worth up to 6.3% of the post-exercise share count.
Every session last week moved at least 5.5%. That is event pricing, not a quiet repricing.
The near-term tape reflects sector caution before two major earnings events. The longer-term debate is Google's purchase ramp.
Calculated at maximum exercise. Most vesting needs $120 billion of purchases through fiscal 2033.
$120B cumulative Google purchase milestones ÷ $8.195B Marvell FY2026 revenue.
| Metric | Q1 actual | Q2 guide |
|---|---|---|
| Revenue | $2.418B | $2.700B ±5% |
| Adj. gross margin | 58.9% | 58.25%–59.25% |
| Adj. diluted EPS | $0.80 | $0.93 ±$0.05 |
| Diluted shares | — | ≈915M |
Results are due after the U.S. close on Aug. 27.
| Firm | Rating | Target |
|---|---|---|
| UBS | Buy | $310 |
| Barclays | Overweight | $275 |
| JPMorgan | Overweight | $240 |
| Raymond James | Strong Buy | $235 |
| 44-analyst average | Strong Buy | $263.94 |
Consensus upside from Friday's close: 11.4%. Published target range: $126–$400.
Market data timestamp: Aug. 24, 2026, 06:29 EDT / 12:29 CEST. Premarket and futures moves are preliminary. Sources: MarketWatch, Marvell 8-K, Marvell Q1 FY2027, StockAnalysis, Investing.com.
| Shares outstanding | 84.91M |
| $600M / $109.68 | 5.47M shares |
| Potential count increase | 6.4% |
| ATM / Friday market cap | 5.7% |
| Value loss / ATM size | 2.14× |
| Metric | Result |
|---|---|
| Revenue | $191.9M · +86% |
| Data-center sales | $107.7M · +140% |
| GAAP margin | 27.7% · -2.6 pts |
| GAAP net loss | $22.8M |
| Stock | Move |
|---|---|
| AAOI | -12.13% |
| COHR | -4.39% |
| LITE | -4.47% |
| Call | Target |
|---|---|
| Rosenblatt · Buy | $220 |
| Needham · Buy | $190 |
| Raymond James · Buy | $178 |
| Northland · Hold | $120 |
| B. Riley · Hold | $109 |
NASDAQ: MU · Memory cycle stress test
21 Aug, 16:00 EDT
Reported 24 Aug, 05:26 EDT
17–21 Aug closes
+56.7% vs last close
Closes: $1,011.75 · $940.76 · $937.11 · $974.33 · $966.78
Peer capital-return disappointment hit a crowded memory trade. New Chinese funding adds a longer-dated supply question.
Micron fiscal Q3 2026. Bars use revenue as the scale anchor, except margin.
| Firm | View | Target |
|---|---|---|
| UBS | Buy | $1,625 |
| BofA | Buy | $1,550 |
| New Street | Buy | $1,250 |
| Consensus | Strong Buy | $1,515 |
47 analysts: 34 Strong Buy, 9 Buy, 4 Hold, 0 Sell.
Micron's earnings case remains strong. The new risk is expectation density: record margins, sustained AI spending and disciplined industry supply are all embedded in the bullish consensus.
Market data: Nasdaq/StockAnalysis and MarketWatch, captured 24 Aug 2026 at 05:26 EDT. Financials: Micron fiscal Q3 2026. Analyst targets: S&P Global/Investing.com snapshot. Premarket data is indicative and may move sharply before the open.
| Measure | Value | From $947.74 |
|---|---|---|
| Consensus | Buy | 39 analysts |
| Average target | $1,077 | +13.7% |
| Low target | $740 | -21.9% |
| High target | $1,315 | +38.8% |
Medicare adds commission potential, store visits and another retention touchpoint. Strong sales and renewal rates fund the experiment.
Rules bar membership bundling. Weak conversion or delayed approval would leave investors paying roughly 46 times forward earnings for the core story alone.
The market needs numbers before treating Medicare as a material earnings driver.
| Eligible shares | 319.0M |
| Aug. 20 volume | 119.0M |
| Aug. 21 volume | 78.1M |
| Two-day move | -1.92% |
| Segment | Revenue | YoY | Share |
|---|---|---|---|
| Connectivity | $4.29B | +66% | 54.9% |
| AI | $2.56B | +247% | 32.8% |
| Space | $0.96B | +29% | 12.3% |
| Segment | Operating result | Capex |
|---|---|---|
| Connectivity | +$1.66B | $1.37B |
| Space | -$0.54B | $1.17B |
| AI | -$1.26B | $15.83B |
| Group | -$0.14B | $18.37B |
| Morgan Stanley / Buy | $300 |
| Clear Street / Buy | $217 |
| DZ Bank / Sell | n/a |
Sources: SpaceX SEC Form 10-Q and Q2 earnings release; SEC IPO filing; MarketWatch; S&P Global Market Intelligence and TipRanks via StockAnalysis. Calculations are preliminary and may differ due to rounding.
The deal may improve manufacturing. The stock still needs rapid order conversion, fewer losses and disciplined integration to defend its premium.
Nine analysts: seven Strong Buy, two Buy.
High short interest can amplify rallies and declines.
Sources: Ondas Q2 2026 and Aran Defense releases; StockAnalysis price history, statistics and analyst forecasts. Company guidance and targets are forecasts, not guarantees.
Consensus: Strong Buy. Twenty-seven of 28 recommendations are Buy or Strong Buy.
The market punished loss of marketing control, then bought the schedule. Thursday's August 27 extended preview is the next measurable checkpoint. Engagement and a firm November 19 release date matter more than the leaked clips themselves.
| Metric | H1 2025 | H1 2026 | Change |
|---|---|---|---|
| Revenue | $117.4bn | $174.4bn | +49% |
| Adjusted EBITDA | $5.43bn | $10.12bn | +86% |
| Adjusted EBIT | $1.80bn | $6.65bn | +269% |
| Funds from operations | $3.15bn | $8.13bn | +158% |
| Net debt | $11.17bn* | $10.19bn | -9% |
27 Aug Jersey register trades ex-distribution.
28 Aug Record date for Jersey and JSE registers.
18 Sep Cash payment date.
Cash: two concurrent distributions of $0.085 each, totalling $0.17 per share.
